Xcout IntelAffini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Subscribe to see Affini-T Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Affini-T Therapeutics, Inc. at a glance
Affini-T Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $175M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $17.6M in October 2024. Xcout tracks 1 named person at Affini-T Therapeutics, Inc., including Joseph Knowles (Chief Executive Officer).
Affini-T Therapeutics, Inc. leadership
- Joseph KnowlesChief Executive Officer
Affini-T Therapeutics, Inc. funding rounds
At least $175M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $17.6M | 8 named | |
| Series A | $175M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Affini-T Therapeutics, Inc. competitors
A few of Affini-T Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Mariana Oncology is a fully integrated radiopharmaceutical company headquartered in Watertown, Massachusetts, that develops precision radioligand therapies to transform cancer treatment.
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Immatics is a biopharmaceutical company that develops T cell-based immunotherapies and bispecific product candidates to treat various types of cancer. The company focuses on precision targeting of the PRAME protein expressed in multiple solid tumors, serving cancer patients with high unmet medical needs.
Get Affini-T Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Affini-T Therapeutics, Inc. in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access